Trial Profile
Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms IMPORTANCE
- 24 Oct 2023 According to trial design presented at the 48th European Society for Medical Oncology Congress, recruitment is estimated to be completed by January 2024.
- 24 Oct 2023 Trial design presented at the 48th European Society for Medical Oncology Congress.
- 11 Jun 2018 New trial record